BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
Source: SeekingAlpha
2025-11-13 18:52:16 ET
More on BioAtla
- BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on BioAtla
- Historical earnings data for BioAtla
- Financial information for BioAtla
Read the full article on Seeking Alpha
For further details see:
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
BioAtla Inc.
NASDAQ: BCAB
BCAB Trading
-0.39% G/L:
$0.1791 Last:
768,348 Volume:
$0.19 Open:
BCAB Latest News
March 02, 2026 07:30:00 am
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
December 31, 2025 07:00:00 am
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
November 21, 2025 12:25:45 am
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
November 13, 2025 04:05:00 pm
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
BCAB Stock Data
$12,399,342
60,967,643
5.51%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
